Bak Cancer Research Results

Bak, BAK or BAK1: Click to Expand ⟱
Source:
Type:
Bak (also known as BAK or BAK1) is a protein that plays a crucial role in regulating cell death.
In cancer, the Bak protein is often inactivated or downregulated, allowing cancer cells to evade apoptosis and continue to proliferate uncontrollably.
NA, Not Available: Click to Expand ⟱
none (reserved)
Scientific Papers found: Click to Expand⟱
1360- Ash,  immuno,    Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
- in-vitro, Lung, H1650 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP↑, p‑eIF2α↑, ICD↑, eff↑,
3201- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*AntiCan↑, *cardioP↑, *neuroP↑, *BioAv↝, *BioAv↓, *BioAv↓, *Dose↝, *Half-Life↝, *BioAv↑, *BBB↑, *hepatoP↓, *other↓, *Inflam↓, *NF-kB↓, *AP-1↓, *iNOS↓, *COX2↓, *ROS↓, *RNS↓, *IL8↓, *JAK↓, *PDGFR-BB↓, *IGF-1R↓, *MMP2↓, *P53↓, *NRF2↑, *TNF-α↓, *IL6↓, *E2Fs↑, *SOD1↑, *SOD2↑, Casp3↑, Cyt‑c↑, PARP↑, DNMTs↓, Telomerase↓, Hif1a↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, TumCP↓, MAPK↓, HGF/c-Met↓, TIMP1↑, HDAC↓, MMP9↓, uPA↓, GlutMet↓, ChemoSen↑, chemoP↑,
1516- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*Dose∅, Half-Life∅, BioAv∅, BBB↑, toxicity∅, eff↓, Apoptosis↑, Casp3↑, Cyt‑c↑, cl‑PARP↑, DNMTs↓, Telomerase↓, angioG↓, Hif1a↓, NF-kB↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, IGF-1↓, H3↓, HDAC1↓, *LDH↓, *ROS↓,
1155- F,    The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations
- Review, NA, NA
*toxicity↓, Casp3↑, Casp7↑, Casp8↑, Casp9↑, VEGF↓, angioG↓, PI3K↓, Akt↓, PARP↑, Bak↑, BID↑, Fas↑, Mcl-1↓, survivin↓, XIAP↓, ERK↓, EMT↓, EM↑, IM↓, Snail↓, Slug↓, Twist↓,
1799- NarG,    Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics
- Review, NA, NA
TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GSH↓, 1,   ICD↑, 1,   ROS↑, 4,  

Mitochondria & Bioenergetics ⓘ

EGF↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis ⓘ

GlutMet↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↑, 2,   BAD↑, 1,   Bak↑, 5,   BAX↑, 4,   Bcl-2↓, 3,   Bcl-xL↓, 2,   BID↑, 1,   Casp3↑, 4,   Casp7↑, 1,   Casp8↑, 2,   Casp9↑, 1,   Cyt‑c↑, 2,   Fas↑, 1,   HGF/c-Met↓, 1,   MAPK↓, 2,   Mcl-1↓, 1,   survivin↓, 2,   Telomerase↓, 2,  

Transcription & Epigenetics ⓘ

H3↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 1,  

DNA Damage & Repair ⓘ

DNMTs↓, 2,   P53↑, 2,   PARP↑, 2,   cl‑PARP↑, 2,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,   ERK↓, 2,   HDAC↓, 1,   HDAC1↓, 1,   IGF-1↓, 1,   mTOR↓, 1,   PI3K↓, 2,   PTEN↑, 2,  

Migration ⓘ

EM↑, 1,   MMP2↓, 1,   MMP9↓, 2,   MMPs↓, 2,   Slug↓, 1,   Snail↓, 1,   TIMP1↑, 1,   TumCP↓, 1,   Twist↓, 1,   uPA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 3,   Hif1a↓, 2,   VEGF↓, 2,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 2,   PD-L1↑, 1,   TNF-α↓, 1,  

Cellular Microenvironment ⓘ

IM↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   BioAv∅, 1,   ChemoSen↑, 2,   eff↓, 2,   eff↑, 1,   Half-Life∅, 2,  

Clinical Biomarkers ⓘ

PD-L1↑, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,   OS↑, 1,   toxicity∅, 1,  
Total Targets: 71

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

NRF2↑, 1,   RNS↓, 1,   ROS↓, 2,   SOD1↑, 1,   SOD2↑, 1,  

Core Metabolism/Glycolysis ⓘ

LDH↓, 1,  

Cell Death ⓘ

iNOS↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

DNA Damage & Repair ⓘ

P53↓, 1,  

Cell Cycle & Senescence ⓘ

E2Fs↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1R↓, 1,  

Migration ⓘ

AP-1↓, 1,   MMP2↓, 1,  

Angiogenesis & Vasculature ⓘ

PDGFR-BB↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   JAK↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,   BioAv↝, 1,   Dose↝, 1,   Dose∅, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 1,   hepatoP↓, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 35

Scientific Paper Hit Count for: Bak, BAK or BAK1
2 EGCG (Epigallocatechin Gallate)
1 Ashwagandha(Withaferin A)
1 immunotherapy
1 Fucoidan
1 Naringin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:632  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page